Seres therapeutics reports fourth quarter and full year 2022 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates. “we are eagerly looking forward to the upcoming potential fda approval of ser-109, an investigational first-in-class oral microbiome therapeutic for recurrent c. difficile infection (rcdi).
MCRB Ratings Summary
MCRB Quant Ranking